Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
Received 21 October 2018
Accepted for publication 22 May 2019
Published 19 June 2019 Volume 2019:13 Pages 1033—1037
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Richard Teofilo Atallah,1 Maria Virginia Castanos,2,3 Richard Najac,2 Eric Donnenfeld4
1Rutgers New Jersey Medical School, Newark, NJ, USA; 2Department of Research, Eye and Ear Infirmary of Mount Sinai, New York, NY, USA; 3Department of Ophthalmology, New York Eye & Ear Infirmary of Mount Sinai, New York, NY, USA; 4Ophthalmic Consultants of Long Island, New York University Medical Center, Garden City, NY, USA
Purpose: To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients.
Setting: Retrospective chart analysis.
Method: A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye disease and were treated with lifitegrast 5% ophthalmic solution for 6 months. Collected symptom data included improvement of eye dryness, tearing, eye pain, fluctuation in vision, foreign body sensation, itching, grittiness, burning and contact lens intolerance if applicable. Collected clinical signs included changes in superficial punctate keratitis, corneal fluorescein staining, conjunctival hyperemia and presence of tear debris.
Results: Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. Improvements were also observed in corneal and conjunctival staining and tear debris for most of the patients reviewed.
Conclusion: Treatment with lifitegrast twice a day for 6 months improved both signs and symptoms of chronic dry eye.
Keywords: lifitegrast, integrin antagonist, dry eye disease, DED, eye dryness, inflammation, ocular surface disease
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]